Open Access<p>Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era</p>
Author(s) -
Sherif Hamdy,
Maged Abdel Naseer,
Hatem S. Shehata,
Nevin Shalaby,
Amr Hassan,
Alaa Elmazny,
Ehab Shaker,
Moda,
Sandra Ahmed,
Mohamed I. Hegazy,
Husam S Mourad,
Ahmed Abdelalim,
Rehab Magdy,
Alshimaa S. Othman,
Doaa Mekkawy,
Nirmeen A. Kishk
Publication year - 2020
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s261753
Subject(s) - medicine , neuromyelitis optica , pandemic , covid-19 , spectrum disorder , virology , multiple sclerosis , immunology , psychiatry , disease , outbreak , infectious disease (medical specialty)
The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.